NeuroendoMedix

NeuroendoMedix is a Swiss clinical-stage biopharmaceutical company dedicated to developing non-hormonal therapies for women's health, with a primary focus on endometriosis and uterine fibroids. The company's lead program, NXM-108, is a small molecule neurokinin 1 (NK1) receptor antagonist currently being evaluated for the treatment of endometriosis-associated pain. Founded by Dr. Ernest Loumaye, a pioneer in reproductive medicine who previously founded ObsEva and PregLem, NeuroendoMedix aims to address significant unmet needs in gynecology. By targeting the tachykinin pathway, the company seeks to provide a novel therapeutic approach that avoids the systemic side effects of traditional hormonal treatments. The management team brings extensive experience in successfully bringing women's health products through clinical development and regulatory approval.